EAM Investors’s Larimar Therapeutics LRMR Stock Holding History

EAM Investors’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-5,428	Closed	-$761K	–	289
2018 Q3	$761K	Buy	5,428 +3,541	+188%	+$430K	0.11%	258
2018 Q2	$232K	Buy	+1,887	New	+$160K	0.04%	286
2015 Q2	–	Sell	-1,938	Closed	-$921K	–	354
2015 Q1	$921K	Buy	+1,938	New	+$920K	0.11%	311

Other funds holding LRMR

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

AVA

Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

EAM Investors's LRMR Position: Q4 2018 in Review

EAM Investors sold out of Larimar Therapeutics (LRMR) in Q4 2018, closing a stake of 5,428 shares — an estimated $761K sold.

EAM Investors first reported a position in LRMR in Q1 2015 and held it in 3 quarters. The position peaked at $921K in Q1 2015. 94 funds tracked by Wall St. Rank hold LRMR as of Q4 2018.

EAM Investors reported no remaining Larimar Therapeutics position as of Q4 2018 after selling out during the quarter.
EAM Investors sold 5,428 Larimar Therapeutics shares in Q4 2018, an estimated $761K.
EAM Investors first reported a position in Larimar Therapeutics in Q1 2015 and held it in 3 quarters.
EAM Investors's Larimar Therapeutics position peaked at $921K in Q1 2015.
94 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2018.

Based on EAM Investors's 13F filing for Q4 2018, filed 13 Feb 2019.